Table 3.
The adverse events of neoadjuvant therapy.
| Characteristics | Number of Neoadjuvant therapy cycles (%) | P value | |
|---|---|---|---|
| 2 (n=150) | 3-4 (n=101) | ||
| Adverse events | |||
| No | 63 (42.0) | 28 (27.7) | 0.021 |
| Yes | 87 (58.0) | 73 (72.3) | |
| CTCAE grade | |||
| Any grade | N=87 | N=73 | 0.869 |
| I | 48 (55.2) | 41 (56.2) | |
| II | 23 (26.4) | 16 (21.9) | |
| III | 9 (10.3) | 10 (13.7) | |
| IV | 7 (8.0) | 6 (8.2) | |
| V | 0 | 0 | |
| Adverse event types | N=87 | N=73 | 0.434 |
| Hepatic dysfunction | 35 (40.2) | 24 (32.9) | |
| Myelosuppression | 25 (28.7) | 22 (30.1) | |
| Thyroid dysfunction | 11 (12.6) | 12 (16.4) | |
| Renal dysfunction | 6 (6.9) | 10 (13.7) | |
| Gastrointestinal reaction | 6 (6.9) | 1 (1.4) | |
| Pneumonia | 1 (1.1) | 0 | |
| Myocarditis | 1 (1.1) | 0 | |
| Erythra | 1 (1.1) | 2 (2.7) | |
| Numbness of extremities | 1 (1.1) | 1 (1.4) | |
| Myositis | 0 | 1 (1.4) | |
CTCAE, Common Terminology Criteria for Adverse Events.